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Simple Summary: A new liver stiffness (LS) based risk prediction model for the development of
hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD), which
consists of old age, low platelet count, aspartate aminotransferase level, and high LS measured by
transient elastography, showed acceptable performance in the internal and external validation in
Asian patients.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased hepatocellular
carcinoma (HCC) risk. We established and validated a liver stiffness (LS)-based risk prediction model
for HCC development in patients with NAFLD. A total of 2666 and 467 patients with NAFLD were
recruited in the training and validation cohorts, respectively. NAFLD was defined as controlled
attenuated parameter ≥238 dB/m by transient elastography. Over a median of 64.6 months, HCC
developed in 22 (0.8%) subjects in the training cohort. Subjects who developed HCC were older
and had higher prevalence of diabetes and cirrhosis, lower platelet count, and higher AST levels
compared to those who did not develop HCC (all p < 0.05). In multivariate analysis, age ≥60 years
(hazard ratio (HR) = 9.1), platelet count <150 × 103/µL (HR = 3.7), and LS ≥9.3 kPa (HR = 13.8)
were independent predictors (all p < 0.05) that were used to develop a risk prediction model for
HCC development, together with AST ≥34 IU/L. AUCs for predicting HCC development at 2, 3,
and 5 years were 0.948, 0.947, and 0.939, respectively. This model was validated in the validation
cohort (AUC 0.777, 0.781, and 0.784 at 2, 3, and 5 years, respectively). The new risk prediction
model for NAFLD-related HCC development showed acceptable performance in the training and
validation cohorts.
Keywords: hepatocellular carcinoma; non-alcoholic fatty liver disease; liver cirrhosis; liver fibrosis;
transient elastography; liver stiffness; risk prediction
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1. Introduction
Currently, non-alcoholic fatty liver disease (NAFLD) is known to affect about one
quarter of the global population [1]. The prevalence of NAFLD in the Republic of Korea
(ROK) is also rapidly increasing, and is estimated to account for approximately 30% of
the general population in the country [2,3]. Approximately 20% of the patients with
NAFLD develop nonalcoholic steatohepatitis (NASH), a chronic inflammatory condition
that is associated with altered lipid metabolism, and has an increased risk of cirrhosis and
hepatocellular carcinoma (HCC) [4,5].
HCC is one of the leading causes of cancer death worldwide [6]. In the ROK, the
number of annual deaths and crude death rate have been reported to increase since 2013
due to liver cancer [7], which is still the second largest cause of cancer mortality and the
most economically burdensome cancer [8]. Indeed, the prevalence of NAFLD-related HCC
appears to have increased over time [4,9,10].
Among the possible risk factors such as old age, diabetes mellitus (DM), alcohol con-
sumption and elevated aspartate aminotransferase (AST), the presence of NASH and cirrho-
sis are known to be the most powerful risk factors for HCC development in NAFLD [11–13].
Of these, NASH is based on histological diagnosis, and cirrhosis is based on ultrasonog-
raphy (US), which might miss advanced liver fibrosis or early compensated liver cirrho-
sis [14]. Recently, liver stiffness (LS) measurement using transient elastography (TE) has
been proven to be a useful tool to assess the risk of NASH and degree of fibrotic burden
in the liver, which are significantly associated with the risk of HCC development [15–18].
However, no risk prediction model for NAFLD-related HCC, especially one that is based
on LS assessment, has been available.
Therefore, in this study, we aimed to identify independent predictors of HCC devel-
opment and also establish and validate a risk prediction model for HCC development in
patients with NAFLD.
2. Materials and Methods
2.1. Patient Eligibility
Between March 2012 and June 2020, subjects who were diagnosed with controlled
attenuated parameter (CAP)-based NAFLD were recruited through a retrospective re-
view using the consecutively registered databases at three high-volume medical centers
(Severance Hospital, Samsung Medical Center, and Gangnam Severance Hospital) as a
training cohort. Data from Kyungpook National University Hospital were included as a
validation cohort.
The exclusion criteria of both cohorts were as follows: (1) age < 19 years; (2) TE
assessment failure using M probe; (3) unreliable TE results; (4) other causes of chronic
hepatitis such as hepatitis B, hepatitis C, autoimmune hepatitis, primary biliary cholangitis
and overlap syndrome; (5) high aminotransferase levels (>300 IU/L); (6) impaired hepatic
function such as high total bilirubin (>3.0 mg/dL) and low albumin (<2.5 g/dL); (7) HCC
development within 6 months after enrollment; (8) liver transplantation within 6 months
after enrollment; (9) insufficient follow-up period of less than 6 months; and (10) insufficient
clinical information (Figure 1).
2.2. Definition
The presence of fatty liver was defined as an elevated CAP ≥ 238 dB/m by TE
(EchoSens, Paris, France) [19–21]. The first date of the diagnosis of NAFLD based on TE was
defined as the index date. The presence of cirrhosis was defined to as findings suggestive of
cirrhosis, including a blunted, nodular liver edge accompanied by splenomegaly (>12 cm)
in the imaging studies such as US, computed tomography (CT) or magnetic resonance
imaging (MRI) that were performed close to the index date.




Figure 1. Flow chart of study subject selection. CAP, controlled attenuated parameter; NAFLD, non-alcoholic fatty liver 
disease; TE, transient elastography; IQR, interquartile range; HCC, hepatocellular carcinoma. 
2.2. Definition 
The presence of fatty liver was defined as an elevated CAP ≥ 238 dB/m by TE 
(EchoSens, Paris, France) [19–21]. The first date of the diagnosis of NAFLD based on TE 
was defined as the index date. The presence of cirrhosis was defined to as findings sug-
gestive of cirrhosis, including a blunted, nodular liver edge accompanied by splenomeg-
aly (>12 cm) in the imaging studies such as US, computed tomography (CT) or magnetic 
resonance imaging (MRI) that were performed close to the index date. 
2.3. TE Assessment 
At each hospital, TE was performed by experienced operators who had conducted at 
least 500 examinations. Patients were examined after overnight fasting using M probes, 
considering the patients’ body mass indices. LS (kPa) and CAP (dB/m) measurements 
were recorded until 10 valid measurements were obtained for each patient. The median 
value was considered representative of the elastic modulus of the liver. Only procedures 
with at least 10 valid measurements, a success rate of at least 60%, and an interquartile 
range (IQR) to median value ratio of 30% were considered reliable [22,23]. 
2.4. HCC 
The outcome of this study was the histological or clinical diagnosis of HCC according 
to the timely guidelines proposed by the Korea Liver Cancer Study group [24]. A positive 
finding for a typical HCC on dynamic CT or MRI was indicated by an increased arterial 
enhancement followed by a decreased enhancement compared with the liver (washout) 
in the portal or equilibrium phase. 
2.5. Statistical Analyses 
Continuous variables such as laboratory test results are expressed as the medians 
(interquartile ranges (IQRs)) and were compared using Student’s t-test or Mann–Whitney 
U test depending on their distribution. Categorical variables are expressed as numbers 
(and percentages) and were evaluated using chi-square test or Fisher’s exact probability 
test. Patients were censored when they ended follow-up, died without developing liver 
cancer, or developed extrahepatic carcinoma. Both univariate and multivariate Cox re-
gressions were employed to analyze the association between HCC development and risk 
factors, and to calculate their hazard ratios (HRs) with 95% confidence intervals (CI). Con-
tinuous variables were categorized by the Youden index or cutoffs that are clinically in 
use. The presence of cirrhosis by imaging studies was not considered in the Cox regression 
analysis because of the possibility of multicollinearity with LS. In the multivariate Cox 
regression model, we considered some known risk factors in the previous reports such as 
old age, DM and elevated AST [11–13,25]. Only few factors were considered in the multi-
variate Cox regression model due to the small number of events [25]. The predictive abil-
ity of the model was assessed by the integrated area under the curve (iAUC) and time-
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2.3. TE Assessment
At each hospital, TE was performed by experienced operators who had conducted at
least 500 examinations. Patients were examined after overnight fasting using M probes,
considering the patients’ body mass indices. LS (kPa) and CAP (dB/m) measurements
were recorded until 10 valid measureme ts were obtained for each patient. The median
value was considered representative of the elastic odulus of the liver. Only procedures
with t least 10 valid measurem nts, a succ ss rat of at least 60%, and an interquartile
range (IQR) to median value ratio of 30% were considered reliable [22,23].
2.4. HCC
The outcome of this study was the histologic l or clinical diagnosis of HCC according
to the timely guidelines proposed by the Korea Liver Cancer Study group [24]. A positive
finding for a typical HCC on dynamic CT or MRI was indicated by an increased arterial
enhancement followed by a decreased enhancement compared with the liver (washout) in
the portal or equilibrium phase.
2.5. Statistical Analyses
Continuous variables such as laboratory test results are expressed as the medians
(interquartile ranges (IQRs)) and were compared using Student’s t-test or Mann–Whitney U
test depending on their distribution. Categorical variables are expressed as numbers (and
percentages) and were evaluated using chi-square test or Fisher’s exact probability test.
Patients were censored when they ended follow-up, died without developing liver cancer,
or developed extrahepatic carcinoma. Both univariate and multivariate Cox regressions
were employed to analyze the association between HCC development and risk factors,
and to calculate their hazard ratios (HRs) with 95% confidence intervals (CI). Continuous
variables were categorized by the Youden index or cutoffs that are clinically in use. The
presence of cirrhosis by imaging studies was not considered in the Cox regression analysis
because of the possibility of multicollinearity with LS. In the multivariate Cox regression
model, we considered some known risk factors in the previous reports such as old age, DM
and elevated AST [11–13,25]. Only few factors were considered in the multivariate Cox
regression model due to the small umber of events [25]. The predictive ability of the model
was assessed by the integrated area under the curve (iAUC) and time-dependent area
under the curve (AUC) at 2, 3, and 5 years after the i dex date [26]. Th model performance
was presented graphically by c lib i n plots hich compared the model prediction
probability with the actu l pr bability. T risk pred ction model was rigorously assessed
ing an internal validation using a bootstrapping meth d and an external validation u ng
data from the valida ion c hort.
Statistical analyses wer perf rmed usi g SAS versio 9.4 (SAS Institute Inc., Cary,
NC, USA) and R package (v. 4.0.4, http://www.r-project.org/, a cessed on 26 July 2021)
software. Two-sided p values < 0.05 were considered to indicate statistical significance.
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3. Results
3.1. Baseline Characteristics
The flow chart of patient selection is shown in Figure 1. A total of 3575 subjects who
were diagnosed with NAFLD based on TE (CAP ≥ 238 dB/m) were considered eligible.
After excluding 909 subjects who met the exclusion criteria, 2666 with NAFLD were finally
included in training cohort. Similarly, 494 subjects who were diagnosed NAFLD were
recruited in the validation cohort. After excluding 27 subjects who met the exclusion
criteria, 467 patients were finally included in the validation cohort.
Baseline characteristics of the training cohort are presented in Table 1. At the index
date, the median age of 1524 (57.2%) male subjects and 1142 (42.8%) female subjects was
52.0 (IQR 41.0–60.0) years. DM, hypertension and cirrhosis were observed in 1029 (38.6%),
1080 (40.5%) and 171 (6.4%) subjects, respectively. TE at the index date showed that the
median LS and CAP were 5.9 (IQR 4.6–7.9) kPa and 303 (IQR 273–331) dB/m.
Table 1. Baseline characteristics in the training cohort.
Variable Total(n = 2666)
Non-HCC
(n = 2644, 99.2%)
HCC
(n = 22, 0.8%) p Value
Age (years) 52.0 (41.0–60.0) 52.0 (41.0–60.0) 70.0 (61.0–72.3) <0.001
Male sex 1524 (57.2) 1509 (57.1) 15 (68.2) 0.204
Diabetes mellitus 1029 (38.6) 1016 (38.4) 13 (59.1) 0.041
Hypertension 1080 (40.5) 1065 (40.3) 15 (68.2) 0.008
BMI (kg/m2) 26.18 (24.17–28.73) 26.2 (24.2–28.7) 27.3 (24.4–29.6) 0.573
Cirrhosis 171 (6.4) 153 (5.8) 18 (81.8) <0.001
Transient elastography
LS (kPa) 5.9 (4.6–7.9) 5.9 (4.6–7.8) 21.5 (13.4–33.0) <0.001
<7.5 1903 (71.4) 1902 (71.9) 1 (4.5)
7.5–9.3 333 (12.4) 332 (12.6) 1 (4.5)
9.3–11.0 127 (4.8) 125 (4.7) 2 (9.1)
11.0–14.0 112 (4.2) 110 (4.2) 2 (9.1)
≥14.0 191 (7.2) 175 (6.6) 16 (72.8)
CAP (dB/m) 303 (273–331) 303 (273–331) 290 (256–325) 0.122
Laboratory test results
Platelet count (×103/µL) 236.0 (200.0–279.0) 237.0 (201.0–279.0) 142.5 (114.8–163.8) <0.001
AST (IU/L) 33 (24–49) 33 (24–49) 47 (32–62) 0.004
ALT (IU/L) 41 (24–68) 41 (24–69) 32 (20–51) 0.200
Total bilirubin (mg/dL) 0.7 (0.5–0.9) 0.7 (0.5–0.9) 1.0 (0.6–1.5) 0.009
Serum albumin (g/dL) 4.5 (4.3–4.7) 4.5 (4.3–4.7) 4.1 (3.7–4.4) 0.001
Prothrombin time (INR) 0.95 (0.91–1.00) 0.95 (0.91–1.00) 1.08 (1.02–1.19) 0.041
Serum creatinine (mg/dL) 0.78 (0.66–0.92) 0.78 (0.66–0.92) 0.76 (0.69–0.92) 0.837
Gamma-GT (mg/dL) 45 (28–73) 44 (28–73) 75 (53–124) 0.010
ALP (IU/L) 64 (53–79) 64 (52–79) 84 (66–103) 0.001
Triglyceride (mg/dL) 155 (110–208) 155 (110–208) 149 (106–168) 0.499
LDL-cholesterol (mg/dL) 121 (94–148) 121 (94–148) 94 (80–115) 0.002
HDL-cholesterol (mg/dL) 45 (39–52) 45 (39–52) 42 (32–49) 0.131
Total cholesterol (mg/dL) 189 (162–216) 189 (163–216) 150 (134.8–191) <0.001
Values are expressed as mean ± standard deviation or n (%). BMI, body mass index; LS, liver stiffness; CAP, controlled attenuated
parameter; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; gamma-GT; ALP, alkaline
phosphatase; gamma-glutamyl transferase; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Subjects in the validation cohort (n = 467) showed a higher proportion of cirrhosis
(9.4% (44/467) vs. 6.4% (171/2666)), higher median LS value (6.5 vs. 5.9 kPa), higher
AST levels (47 vs. 33 IU/L) and higher alanine aminotransferase levels (57 vs. 41 IU/L)
compared to those in the training cohort (all p < 0.05) (Table S1).
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3.2. Comparison between Subjects Who Developed HCC and Those Who Did Not
During the mean follow-up period of 60.7 ± 25.7 months in the training cohort,
HCC developed in 22 (0.8%) subjects (approximately 1.63 per 1000 patient years). The
cumulative 2-, 3- and 5-year HCC incidence rates in the training cohort were 8 (0.3%), 13
(0.5%), and 17 (0.6%), respectively. The subjects who developed HCC (n = 22, 0.8%) showed
significantly older age (median 70.0 vs. 52.0 years); higher prevalence of DM (59.1% vs.
38.4%), hypertension (68.2% vs. 40.3%), and cirrhosis (81.8% vs. 5.8%); higher LS value
(median 21.5 vs. 5.9 kPa); lower platelet count (median 142.5 vs. 237.0 × 103/µL); and
higher AST levels (median 47 vs. 33 IU/L), compared to those who did not develop HCC
(all p < 0.05) (Table 1).
In addition, during the mean follow-up period of 28.2 ± 20.8 months, nine (1.9%) sub-
jects developed HCC in the validation cohort (approximately 8.19 per 1000 patient years).
3.3. Risk Factors of HCC Development in the Training Cohort
Univariate Cox regression analysis revealed that variables such as age, presence
of cirrhosis, higher LS, lower platelet count, higher AST level, lower serum albumin,
higher total bilirubin and higher total cholesterol were significantly associated with HCC
development (all p < 0.05) (Table S2). Subsequent multivariate analyses based on significant
variables in the univariate analysis revealed three variables, including age ≥ 60 years (HR
= 9.143 (95% CI 2.055–40.684, p = 0.004), platelet count < 150 × 103/µL (HR = 3.670 (95% CI
1.295–10.402), p = 0.001), and LS ≥ 9.3 kPa (HR = 13.757 (95% CI 2.826–66.955) p = 0.001)
that were independently associated with an increased risk of HCC development (Table 2).





p Value Hazard Ratio (95% CI)
Age ≥ 60 (vs. <60) years <0.001 0.004 9.143 (2.055, 40.684)
Liver stiffness ≥ 9.3 (vs. <9.3) kPa <0.001 0.001 13.757 (2.826, 66.955)
Platelet count < 150 (vs. ≥150) × 103/µL <0.001 0.014 3.670 (1.295, 10.402)
AST ≥ 34 (vs. <34) IU/L 0.068 0.395 1.583 (0.549, 4.560)
Serum albumin < 3.4 (vs. ≥3.4) g/dL <0.001 0.161 2.699 (0.674, 10.803)
Total bilirubin ≥ 2.0 (vs. <2.0) mg/dL <0.001 0.566 1.485 (0.385, 5.737)
Total cholesterol ≥ 168 (vs. <168) mg/dL <0.001 0.259 0.560 (0.204, 1.534)
CI, confidence interval; AST, aspartate aminotransferase.
3.4. Establishment of a New Risk Prediction Model for HCC
Based on the multivariate Cox regression analysis, three predictive models (Models 1, 2
and 3) for HCC development were established, which incorporated the three independently
associated factors (age, platelet count, and categorized LS), together with AST level (>34
IU/mL), which is a closely associated with HCC risk among patients with NAFLD [13]
(Tables S3 and S4). The 2-, 3- and 5-year AUCs and iAUC for predicting HCC development
in the training cohort were 0.943, 0.941, 0.933 and 0.939 in Model 1, respectively; 0.948,
0.947 0.939 and 0.944 in Model 2, respectively; and 0.945, 0.944, 0.940 and 0.942 in Model 3,
respectively (Table S5).
Considering the stratified risk of categorized LS, Model 2 was selected as a novel risk
prediction model for HCC development among subjects with NAFLD, which categorized
LS as <9.3 kPa, 9.3–11.0 kPa, 11.0–14.0 kPa, and ≥14.0 kPa. This model’s score ranged from
0 to 227, and when the sum of the scores was more than 142, 195, 212 and 223 the 5-year
probability of developing HCC was calculated to be 1%, 10%, 20% and 30%, respectively
(Figure 2 and Table S4).
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respectively (Table 3). Calibration plots for the model for predicting 2-, 3-, and 5-year
HCC development showed that the predicted probabilities were very close to the observed
incidence rates (Figure S1).
Table 3. Time-dependent AUC of the selected risk prediction model in the training cohort, internal validation using the
tstra et , a exter al vali ation.
AUC Training C hort Internal Validatio tstrap) lidation Cohort
iAUC 0.944 (0.9 9, 0.979) 0.954 (0.916, 0. ) . 2 (0.610, 0.954)
2 yr AUC 0.948 (0.917, 0.979) 0.956 (0.922, 0. ) . 7 (0.606, 0.948)
3 yr AUC 0.947 (0.914, 0.980) 0.955 (0.920, 0.983) 0.781 (0.614, 0.948)
5 yr AUC 0.939 (0.900, 0.978) 0.950 (0.909, 0.983) 0.784 (0.619, 0.949)
Values are expressed as AUC (95% confidence intervals). AUC, area under the receiver operating characteristic curve; iAUC,
integrated AUC.
In the validation cohort (n = 467), the acceptable performance of the model was
verified by analyzing the iAUCs (0.782). The 2-, 3- and 5-year AUC were 0.777, 0.781 and
0.784, respectively (Table 3). The calibration plot for the validation cohort showed that the
predicted probabilities were also very close to the observed incidence rates (Figure S1).
The performance and calibration plots of the non-selected models were also acceptable
in the internal validation using bootstrap sampling and external validation (Table S5,
Figures S2 and S3).
4. Discussion
In this retrospective study, we developed and validated a new risk prediction model
using potential risk factors for HCC development among patients with NAFLD, by analyz-
ing of multicenter data from the independent high-volume medical centers in the ROK.
The two study cohorts included non-significant alcohol-experienced patients with fatty
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liver, who were evaluated for hepatic fibrosis using TE. Although several recent studies
have suggested varying cutoff values [27], we selected the low cutoff of CAP (238 dB/m)
to distinguish non-steatosis (S0) according to the previous clinicopathology study [19], due
to the possibility of hepatic fat loss in advanced nonalcoholic steatohepatitis and cirrhosis,
which have an increased HCC risk. The incidence rate of HCC among subjects in the
training and validation cohorts was approximately 1.63 and 8.19 per 1000 patient years,
respectively. Multivariate Cox analysis in the training cohort revealed independent risk
factors for HCC development such as old age, low platelet counts and LS. After comparing
the possible risk prediction models created by combining these risk factors and other
variables, a risk prediction model was finally established using age, platelet count, LS and
AST. The performance of our newly proposed risk prediction model for NAFLD-HCC
was high (iAUC = 0.950) in the internal validation using the bootstrap method and also
acceptable (iAUC = 0.728) in the validation cohort.
Our study has several important clinical implications. First, the incidence rate of HCC
in our current study was relatively higher than that reported by Kim et al. as 0.23 per
1000 patient years in 8721 patients with NAFLD identified from a health checkup in a
healthy population in the ROK [15]. Although the higher incidence rates were reported
to range from 1.11 to 45 per 1000 patient years in the subgroups with mainly NASH and
cirrhosis [5,12,28–30]. Western countries reported incidence rates ranging from 0.08 to
0.6 per 1000 patient years in patients with mainly NAFLD rather than NASH [5,12,28,31],
which is relatively lower than the results of our study. Although the exact reason for this
phenomenon is unclear, it can be explained in part by the potentially higher proportion of
patients at high-risk for NASH with unfavorable medical conditions (such as steatohepatitis
and liver fibrosis) in large-volume tertiary medical centers, who require regular follow-up.
Indeed, the significant fibrosis burden in our study (28.6% and 36.4%) was higher than
those in previous reports (2.8–20.4%) [13,28,32,33]. Although HCC development was not
frequently observed, long-term follow-up of a large-group of patients with NAFLD and
unfavorable medical conditions could enable the elucidation of risk factors and construction
of predictive models.
Second, this study was conducted with a large number of patients who were followed
for a long-term period in high-volume hospitals in the ROK. In addition, all subjects
in our study had information regarding TE results to assess the degree of liver fibrosis
and diagnose NAFLD with higher accuracy and subjectivity [2,16,20,34]. Indeed, to the
best of our knowledge, this study is the first to conduct risk stratification of HCC in
patients with NAFLD based on TE results. Due to such high accuracy, subjectivity, and
reproducibility, various TE-based risk prediction models for hepatitis B-related HCC have
been proposed [18,35].
Third, the incidence rate of HCC in the validation cohort was significantly higher
than that in the training cohort, probably due to the unfavorable clinical characteristics
such as higher prevalence of cirrhosis, higher LS, and higher aminotransferase levels in the
validation cohort. Despite of these variable clinical characteristics and follow-up durations
between the training and validation cohorts, our newly proposed model showed acceptable
performance in the validation cohort. Although the small number of HCC development
in the validation cohort (n = 9, 1.9%) and relatively short follow-up duration might affect
the decreased iAUC in the validation cohort (iAUC = 0.944 to 0.782), the discriminatory
performance was still acceptable. In addition, the calibration plot of HCC development
indicated that the model provided unbiased estimation results. Moreover, our model
showed consistent AUCs at 2, 3 and 5 years in both the training and validation cohorts,
suggesting that the good performance of our risk prediction model may be consistent
over time.
Fourth, our risk prediction model for HCC development can be easily applied to pa-
tients with NAFLD who are on regular medical follow-up, since it uses simple information
that is readily available, such as the patient’s age, platelet count and AST level, except LS
assessment using TE, which is usually available in tertiary medical centers. The derived
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risk factors in this study are also well reported in the literature [11–13,15,16]. Furthermore,
the model uses LS by TE and can indicate the presence of cirrhosis instead. Notably, we
revealed that in addition to the high LS values (>11.0 or >14.0 kPa) corresponding to
cirrhosis, the LS values corresponding to advanced fibrosis (≥9.6 kPa) are also possible
risk factors for the development of HCC in NAFLD. The results suggest that there might
be a risk of HCC development in patients with high LS values, even if they do not have
cirrhotic features on US. TE results could compensate for the inadequate scan quality of US
in patients with obesity or cirrhosis [36].
Our study had some limitations. First, this study was based on a retrospective setting
that included only subjects who underwent TE, and could have been potentially subject
to selection bias. Second, in addition to the extremely small proportion of subjects with
XL probe, the availability of XL probe in only one institutes has limited further analysis
regarding XL probe. However, this might limit obese subjects who are in greater need
to be examined by TE. Third, we did not consider the on-therapy changes in risk factors,
such as fibrosis regression or improvement in necroinflammation after weight reduction.
Fourth, it is unclear whether LS by TE represents actual intrahepatic fibrosis, since our data
lacked paired liver biopsies. In addition, due to the absence of histological information,
we could not investigate the influence of NASH on the risk of HCC in our study. Fifth,
the cost of TE can make our risk prediction model difficult for anyone to use clinically.
Clinicians may use cirrhosis instead of the highest LS categorization score. Further studies
are needed to investigate whether fibrosis assessment based on TE can be substituted with
other noninvasive surrogates such as the fibrosis-4 index for application in primary care
clinics [2,15].
5. Conclusions
This study developed and validated a risk prediction model using simple information
that is readily available such as age, platelet count, AST level, and LS by TE, to predict HCC
in patients with NAFLD. Despite the heterogeneity of the patient characteristics between
the two cohorts, this model showed acceptable performance in the training and validation
cohorts. Our risk prediction model may provide information regarding the classification of
patients with NAFLD for whom medical follow-up strategies to detect HCC development
should be cautioned.
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cellular carcinoma in patients with non-alcoholic fatty liver disease using variables incorporated in
the prediction model, Table S4: Nomogram for each risk prediction model for HCC development,
Table S5: Time-dependent AUCs and iAUC of each risk prediction model in the training cohort,
internal validation using the bootstrap method, and external validation, Figure S1: Calibration plots
of the risk prediction model at 2-, 3-, and 5-year; iAUC and time-dependent receiver operational
characteristics curves in training (A) and validation cohort (B). AUC, area under the receiver op-
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time-dependent receiver operational characteristics curves of prediction model 1 (A) and 3 (B) in
the training cohort, Figure S3: Calibration plots, iAUCs and time-dependent receiver operational
characteristics curves of prediction model 1 (A) and 3 (B) in the validation cohort.
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